{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:36Z","timestamp":1792794996824,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40263-024-01141-9","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T04:39:56Z","timestamp":1742531996000},"page":"9-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Narcolepsy: Beyond the Classic Pentad"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4494-0195","authenticated-orcid":false,"given":"Anne Marie","family":"Morse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654\u201362.","journal-title":"N Engl J Med"},{"key":"1141_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccm.2010.02.014","volume":"31","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31:371\u201381.","journal-title":"Clin Chest Med"},{"key":"1141_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy-clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15:519\u201339.","journal-title":"Nat Rev Neurol"},{"key":"1141_CR4","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/ene.14888","volume":"28","author":"CLA Bassetti","year":"2021","unstructured":"Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28:2815\u201330.","journal-title":"Eur J Neurol"},{"key":"1141_CR5","first-page":"233","volume":"10","author":"MJ Thorpy","year":"2017","unstructured":"Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy: Implications for managed care. Am Health Drug Benefits. 2017;10:233\u201341.","journal-title":"Am Health Drug Benefits."},{"key":"1141_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.sleep.2021.06.008","volume":"84","author":"MM Ohayon","year":"2021","unstructured":"Ohayon MM, Thorpy MJ, Carls G, et al. The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis. Sleep Med. 2021;84:405\u201314.","journal-title":"Sleep Med"},{"key":"1141_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874620901306010001","volume":"6","author":"M Morandin","year":"2013","unstructured":"Morandin M, Bruck D. Understanding automatic behavior in narcolepsy: new insights using a phenomenological approach. Open Sleep J. 2013;6:1\u20137.","journal-title":"Open Sleep J."},{"key":"1141_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","volume":"10","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers Y, Siegel JM, Lopez R, et al. Cataplexy-clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10:386\u201395.","journal-title":"Nat Rev Neurol"},{"key":"1141_CR9","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awr244","volume":"134","author":"G Plazzi","year":"2011","unstructured":"Plazzi G, Pizza F, Palaia V, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain. 2011;134:3477\u201389.","journal-title":"Brain"},{"key":"1141_CR10","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.","edition":"3"},{"key":"1141_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1071\/PY03007","volume":"9","author":"D Bruck","year":"2003","unstructured":"Bruck D, Costa A. The natural history of health and symptoms in narcolepsy: a 10-year longitudinal study. Aust J Prim Health. 2003;9:59\u201367.","journal-title":"Aust J Prim Health"},{"key":"1141_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0883073819836548","volume":"34","author":"S Levy","year":"2019","unstructured":"Levy S, McArthur I, Crow B, Zuberi S. Factors influencing time to diagnosis in childhood narcolepsy type 1. J Child Neurol. 2019;34:440\u20135.","journal-title":"J Child Neurol"},{"key":"1141_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/spen.2001.29475","volume":"8","author":"MS Wise","year":"2001","unstructured":"Wise MS, Lynch J. Narcolepsy in children. Semin Pediatr Neurol. 2001;8:198\u2013206.","journal-title":"Semin Pediatr Neurol."},{"key":"1141_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","volume":"43","author":"ST Szabo","year":"2019","unstructured":"Szabo ST, Thorpy MJ, Mayer G, et al. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev. 2019;43:23\u201336.","journal-title":"Sleep Med Rev"},{"key":"1141_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6:991\u20137.","journal-title":"Nat Med"},{"key":"1141_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/sleep\/32.8.993","volume":"32","author":"TC Thannickal","year":"2009","unstructured":"Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009;32:993\u20138.","journal-title":"Sleep"},{"key":"1141_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469\u201374.","journal-title":"Neuron"},{"key":"1141_CR18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, 5th edition: DSM-5","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition: DSM-5. Washington, DC: American Psychiatric Publishing; 2013."},{"key":"1141_CR19","volume-title":"International classification of sleep disorders\u2014third edition text revision, summary of diagnostic criteria changes. 3rd-TR ed","author":"American Academy of Sleep Medicine","year":"2023","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders\u2014third edition text revision, summary of diagnostic criteria changes. 3rd-TR ed. Darien: American Academy of Sleep Medicine; 2023."},{"key":"1141_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1","volume":"62","author":"JG Sutcliffe","year":"2000","unstructured":"Sutcliffe JG, de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res. 2000;62:161\u20138.","journal-title":"J Neurosci Res"},{"key":"1141_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fphys.2017.00357","volume":"8","author":"S Chieffi","year":"2017","unstructured":"Chieffi S, Carotenuto M, Monda V, et al. Orexin system: the key for a healthy life. Front Physiol. 2017;8:357.","journal-title":"Front Physiol"},{"key":"1141_CR22","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996\u201310015.","journal-title":"J Neurosci"},{"key":"1141_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0167-0115(01)00348-2","volume":"104","author":"M Sz\u00e9kely","year":"2002","unstructured":"Sz\u00e9kely M, P\u00e9terv\u00e1ri E, Balask\u00f3 M, et al. Effects of orexins on energy balance and thermoregulation. Regul Pept. 2002;104:47\u201353.","journal-title":"Regul Pept"},{"key":"1141_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature04071","volume":"437","author":"GC Harris","year":"2005","unstructured":"Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005;437:556\u20139.","journal-title":"Nature"},{"key":"1141_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573\u201385.","journal-title":"Cell"},{"key":"1141_CR26","doi-asserted-by":"publisher","first-page":"12642","DOI":"10.1523\/JNEUROSCI.2120-10.2010","volume":"30","author":"A Yamanaka","year":"2010","unstructured":"Yamanaka A, Tabuchi S, Tsunematsu T, et al. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010;30:12642\u201352.","journal-title":"J Neurosci"},{"key":"1141_CR27","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1523\/JNEUROSCI.1607-04.2004","volume":"24","author":"C Acuna-Goycolea","year":"2004","unstructured":"Acuna-Goycolea C, van den Pol A. Glucagon-like peptide 1 excites hypocretin\/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. J Neurosci. 2004;24:8141\u201352.","journal-title":"J Neurosci"},{"key":"1141_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.793004","volume":"14","author":"X-Y Chen","year":"2021","unstructured":"Chen X-Y, Chen L, Yang W, Xie A-M. GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions. Front Mol Neurosci. 2021;14: 793004.","journal-title":"Front Mol Neurosci"},{"key":"1141_CR29","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/03007995.2016.1208643","volume":"32","author":"C Ruoff","year":"2016","unstructured":"Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Curr Med Res Opin. 2016;32:1611\u201322.","journal-title":"Curr Med Res Opin"},{"key":"1141_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2018.06.008","volume":"85","author":"G Plazzi","year":"2018","unstructured":"Plazzi G, Clawges HM, Owens JA. Clinical characteristics and burden of illness in pediatric patients with narcolepsy. Pediatr Neurol. 2018;85:21\u201332.","journal-title":"Pediatr Neurol"},{"key":"1141_CR31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.5665\/sleep.2080","volume":"35","author":"O Andlauer","year":"2012","unstructured":"Andlauer O, Moore HT, Hong SC, et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012;35:1247\u201355.","journal-title":"Sleep"},{"key":"1141_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/sleep\/30.8.969","volume":"30","author":"MS Heier","year":"2007","unstructured":"Heier MS, Evsiukova T, Vilming S, et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep. 2007;30:969\u201373.","journal-title":"Sleep"},{"key":"1141_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jsmc.2016.10.001","volume":"12","author":"M Thorpy","year":"2017","unstructured":"Thorpy M, Morse AM. Reducing the clinical and socioeconomic burden of narcolepsy by earlier diagnosis and effective treatment. Sleep Med Clin. 2017;12:61\u201371.","journal-title":"Sleep Med Clin"},{"key":"1141_CR34","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1212\/WNL.57.11.2029","volume":"57","author":"Y Dauvilliers","year":"2001","unstructured":"Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57:2029\u201333.","journal-title":"Neurology"},{"key":"1141_CR35","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3949\/ccjm.85a.17086","volume":"85","author":"EC Golden","year":"2018","unstructured":"Golden EC, Lipford MC. Narcolepsy: diagnosis and management. Cleve Clin J Med. 2018;85:959\u201369.","journal-title":"Cleve Clin J Med"},{"key":"1141_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5664\/jcsm.6494","volume":"13","author":"K Maski","year":"2017","unstructured":"Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13:419\u201325.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00737-023-01371-8","volume":"27","author":"M Ferrara","year":"2024","unstructured":"Ferrara M, Curtarello EMA, Gentili E, et al. Sex differences in schizophrenia-spectrum diagnoses: results from a 30-year health record registry. Arch Womens Ment Health. 2024;27:11\u201320.","journal-title":"Arch Womens Ment Health"},{"key":"1141_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3899\/jrheum.160825","volume":"44","author":"V Jovani","year":"2017","unstructured":"Jovani V, Blasco-Blasco M, Ruiz-Cantero MT, Pascual E. Understanding how the diagnostic delay of spondyloarthritis differs between women and men: a systematic review and metaanalysis. J Rheumatol. 2017;44:174\u201383.","journal-title":"J Rheumatol"},{"key":"1141_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/jsr.12044","volume":"22","author":"G Luca","year":"2013","unstructured":"Luca G, Haba-Rubio J, Dauvilliers Y, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res. 2013;22:482\u201395.","journal-title":"J Sleep Res"},{"key":"1141_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac126","author":"MH Schmidt","year":"2022","unstructured":"Schmidt MH, Bassetti CLA. Gender differences in narcolepsy: What are recent findings telling us? Sleep. 2022;45(12):zsac126.","journal-title":"Sleep"},{"key":"1141_CR41","doi-asserted-by":"publisher","first-page":"e14157","DOI":"10.1111\/jsr.14157","volume":"33","author":"F Ingravallo","year":"2024","unstructured":"Ingravallo F, Bassi C, Zenesini C, et al. Sex disparities in clinical features and burden of narcolepsy type 1. J Sleep Res. 2024;33:e14157.","journal-title":"J Sleep Res"},{"key":"1141_CR42","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1210\/endo.142.12.8558","volume":"142","author":"SH Russell","year":"2001","unstructured":"Russell SH, Small CJ, Kennedy AR, et al. Orexin A interactions in the hypothalamo-pituitary gonadal axis. Endocrinology. 2001;142:5294\u2013302.","journal-title":"Endocrinology"},{"key":"1141_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00213-022-06296-1","volume":"240","author":"HJJ Kim","year":"2023","unstructured":"Kim HJJ, Dickie SA, Laprairie RB. Estradiol-dependent hypocretinergic\/orexinergic behaviors throughout the estrous cycle. Psychopharmacology. 2023;240:15\u201325.","journal-title":"Psychopharmacology"},{"key":"1141_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5935\/1984-0063.20170004","volume":"10","author":"J Bhattarai","year":"2017","unstructured":"Bhattarai J, Sumerall S. Current and future treatment options for narcolepsy: a review. Sleep Sci. 2017;10:19\u201327.","journal-title":"Sleep Sci."},{"key":"1141_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","volume":"34","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34:9\u201327.","journal-title":"CNS Drugs"},{"key":"1141_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14656566.2018.1561861","volume":"20","author":"S de Biase","year":"2019","unstructured":"de Biase S, Gigli GL, Valente M. Important decisions in choosing the pharmacotherapy for narcoleptics. Expert Opin Pharmacother. 2019;20:483\u20136.","journal-title":"Expert Opin Pharmacother"},{"key":"1141_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","volume":"16","author":"MJ Thorpy","year":"2015","unstructured":"Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9\u201318.","journal-title":"Sleep Med"},{"key":"1141_CR48","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:1881\u201393.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR49","volume-title":"Xywav\u2122 (calcium, magnesium, potassium, and sodium oxybate). Full Prescribing Information","author":"Jazz Pharmaceuticals","year":"2023","unstructured":"Jazz Pharmaceuticals. Xywav\u2122 (calcium, magnesium, potassium, and sodium oxybate). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals Inc; 2023."},{"key":"1141_CR50","volume-title":"LUMRYZ\u2122 (sodium oxybate for extended-release oral suspension, CIII). Full Prescribing Information","author":"Avadel Pharmaceuticals","year":"2023","unstructured":"Avadel Pharmaceuticals. LUMRYZ\u2122 (sodium oxybate for extended-release oral suspension, CIII). Full Prescribing Information. Chesterfield: Avadel Pharmaceuticals; 2023."},{"key":"1141_CR51","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705\u201311.","journal-title":"Sleep"},{"key":"1141_CR52","first-page":"419","volume":"7","author":"K Srivastava","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419\u201334.","journal-title":"Patient Prefer Adherence"},{"key":"1141_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-021-01051-4","volume":"18","author":"C Franceschini","year":"2021","unstructured":"Franceschini C, Pizza F, Cavalli F, Plazzi G. A practical guide to the pharmacological and behavioral therapy of narcolepsy. Neurotherapeutics. 2021;18:6\u201319.","journal-title":"Neurotherapeutics"},{"key":"1141_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/NSS.S162762","volume":"12","author":"EC Barker","year":"2020","unstructured":"Barker EC, Flygare J, Paruthi S, Sharkey KM. Living with narcolepsy: current management strategies, future prospects, and overlooked real-life concerns. Nat Sci Sleep. 2020;12:453\u201366.","journal-title":"Nat Sci Sleep."},{"key":"1141_CR55","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7790\/ejap.v1i1.5","volume":"1","author":"H Culbertson","year":"2005","unstructured":"Culbertson H, Bruck D. Narcolepsy and disruption to social functioning. E-J Appl Psychol. 2005;1:14\u201322.","journal-title":"E-J Appl Psychol."},{"key":"1141_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101510","volume":"59","author":"M Filardi","year":"2021","unstructured":"Filardi M, D\u2019Anselmo A, Agnoli S, et al. Cognitive dysfunction in central disorders of hypersomnolence: a systematic review. Sleep Med Rev. 2021;59: 101510.","journal-title":"Sleep Med Rev"},{"key":"1141_CR57","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1212\/WNL.0000000000205813","volume":"102","author":"P Maruff","year":"2024","unstructured":"Maruff P, Latzman RD, Gattuso J, et al. The nature and magnitude of cognitive impairment in narcolepsy and idiopathic hypersomnia: a meta-analysis (S18.002). Neurology. 2024;102:5435.","journal-title":"Neurology"},{"key":"1141_CR58","volume-title":"The voice of the patient: narcolepsy","author":"Center for Drug Evaluation and Research (CDER)","year":"2014","unstructured":"Center for Drug Evaluation and Research (CDER). The voice of the patient: narcolepsy. Silver Spring: US Food and Drug Administration; 2014."},{"key":"1141_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.5664\/jcsm.11014","volume":"20","author":"R Rosenberg","year":"2024","unstructured":"Rosenberg R, Thorpy MJ, Doghramji K, Morse AM. Brain fog in central disorders of hypersomnolence: a review. J Clin Sleep Med. 2024;20:643\u201351.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38: 101019.","journal-title":"EClinicalMedicine."},{"key":"1141_CR61","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.sleep.2013.03.002","volume":"14","author":"MM Ohayon","year":"2013","unstructured":"Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14:488\u201392.","journal-title":"Sleep Med"},{"key":"1141_CR62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4088\/JCP.15m10262","volume":"78","author":"CM Ruoff","year":"2017","unstructured":"Ruoff CM, Reaven NL, Funk SE, et al. High rates of psychiatric comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study of 9,312 patients in the United States. J Clin Psychiatry. 2017;78:171\u20136.","journal-title":"J Clin Psychiatry"},{"key":"1141_CR63","doi-asserted-by":"publisher","first-page":"zpae067","DOI":"10.1093\/sleepadvances\/zpae067","volume":"5","author":"MC Lipford","year":"2024","unstructured":"Lipford MC, Ip W, Awasthi S, et al. Demographic characteristics and comorbidities of patients with narcolepsy: a propensity-matched cohort study. Sleep Adv. 2024;5:zpae067.","journal-title":"Sleep Adv."},{"key":"1141_CR64","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s11325-016-1365-5","volume":"20","author":"L Dunne","year":"2016","unstructured":"Dunne L, Patel P, Maschauer EL, et al. Misdiagnosis of narcolepsy. Sleep Breath. 2016;20:1277\u201384.","journal-title":"Sleep Breath."},{"key":"1141_CR65","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.genhosppsych.2009.08.007","volume":"32","author":"HA Fortuyn","year":"2010","unstructured":"Fortuyn HA, Lappenschaar MA, Furer JW, et al. Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psychiatry. 2010;32:49\u201356.","journal-title":"Gen Hosp Psychiatry"},{"key":"1141_CR66","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.5664\/jcsm.10212","volume":"18","author":"RD Davidson","year":"2022","unstructured":"Davidson RD, Biddle K, Nassan M, et al. The impact of narcolepsy on social relationships in young adults. J Clin Sleep Med. 2022;18:2751\u201361.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR67","doi-asserted-by":"publisher","first-page":"e2755","DOI":"10.1212\/WNL.0000000000010737","volume":"95","author":"L Barateau","year":"2020","unstructured":"Barateau L, Lopez R, Chenini S, et al. Depression and suicidal thoughts in untreated and treated narcolepsy: systematic analysis. Neurology. 2020;95:e2755\u201368.","journal-title":"Neurology"},{"key":"1141_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1212\/WNL.0000000000000045","volume":"82","author":"D Grimaldi","year":"2014","unstructured":"Grimaldi D, Silvani A, Benarroch EE, Cortelli P. Orexin\/hypocretin system and autonomic control: new insights and clinical correlations. Neurology. 2014;82:271\u20138.","journal-title":"Neurology"},{"key":"1141_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13736","volume":"32","author":"J Wang","year":"2023","unstructured":"Wang J, Yan Z, Dong X, et al. Diurnal changes in blood pressure and heart rate in children with narcolepsy with cataplexy. J Sleep Res. 2023;32: e13736.","journal-title":"J Sleep Res"},{"key":"1141_CR70","doi-asserted-by":"publisher","first-page":"1107632","DOI":"10.3389\/fneur.2023.1107632","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sun Q, Tang Q, et al. Progress of autonomic disturbances in narcolepsy type 1. Front Neurol. 2023;14:1107632.","journal-title":"Front Neurol"},{"key":"1141_CR71","doi-asserted-by":"publisher","first-page":"zsz187","DOI":"10.1093\/sleep\/zsz187","volume":"42","author":"L Barateau","year":"2019","unstructured":"Barateau L, Chenini S, Evangelista E, et al. Clinical autonomic dysfunction in narcolepsy type 1. Sleep. 2019;42:zsz187.","journal-title":"Sleep"},{"key":"1141_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.634660","volume":"12","author":"F Deng","year":"2021","unstructured":"Deng F, Zhang Y, Zhang R, et al. Compromised dynamic cerebral autoregulation in patients with central disorders of hypersomnolence. Front Neurol. 2021;12: 634660.","journal-title":"Front Neurol"},{"key":"1141_CR73","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuroimage.2005.06.019","volume":"28","author":"EY Joo","year":"2005","unstructured":"Joo EY, Hong SB, Tae WS, et al. Cerebral perfusion abnormality in narcolepsy with cataplexy. Neuroimage. 2005;28:410\u20136.","journal-title":"Neuroimage"},{"key":"1141_CR74","doi-asserted-by":"publisher","first-page":"e38977","DOI":"10.1371\/journal.pone.0038977","volume":"7","author":"Y Dauvilliers","year":"2012","unstructured":"Dauvilliers Y, Jaussent I, Krams B, et al. Non-dipping blood pressure profile in narcolepsy with cataplexy. PLoS ONE. 2012;7:e38977.","journal-title":"PLoS ONE"},{"key":"1141_CR75","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.smrv.2010.05.002","volume":"15","author":"G Plazzi","year":"2011","unstructured":"Plazzi G, Moghadam KK, Maggi LS, et al. Autonomic disturbances in narcolepsy. Sleep Med Rev. 2011;15:187\u201396.","journal-title":"Sleep Med Rev"},{"key":"1141_CR76","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10286-020-00718-w","volume":"30","author":"C Rocchi","year":"2020","unstructured":"Rocchi C, Placidi F, Del Bianco C, et al. Autonomic symptoms, cardiovascular and sudomotor evaluation in de novo type 1 narcolepsy. Clin Auton Res. 2020;30:557\u201362.","journal-title":"Clin Auton Res"},{"key":"1141_CR77","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/jnnp.60.5.576","volume":"60","author":"D Bruck","year":"1996","unstructured":"Bruck D, Parkes J. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry. 1996;60:576\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1141_CR78","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1016\/j.jacc.2021.03.005","volume":"77","author":"EM Garland","year":"2021","unstructured":"Garland EM, Gamboa A, Nwazue VC, et al. Effect of high dietary sodium intake in patients with postural tachycardia syndrome. J Am Coll Cardiol. 2021;77:2174\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"1141_CR79","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fneur.2014.00118","volume":"5","author":"J Mallien","year":"2014","unstructured":"Mallien J, Isenmann S, Mrazek A, Haensch CA. Sleep disturbances and autonomic dysfunction in patients with postural orthostatic tachycardia syndrome. Front Neurol. 2014;5:118.","journal-title":"Front Neurol"},{"key":"1141_CR80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrneurol.2011.187","volume":"8","author":"CJ Mathias","year":"2011","unstructured":"Mathias CJ, Low DA, Iodice V, et al. Postural tachycardia syndrome-current experience and concepts. Nat Rev Neurol. 2011;8:22\u201334.","journal-title":"Nat Rev Neurol"},{"key":"1141_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102906","volume":"237","author":"EL Williams","year":"2022","unstructured":"Williams EL, Raj SR, Schondorf R, et al. Salt supplementation in the management of orthostatic intolerance: vasovagal syncope and postural orthostatic tachycardia syndrome. Auton Neurosci. 2022;237: 102906.","journal-title":"Auton Neurosci"},{"key":"1141_CR82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.sleep.2017.11.1125","volume":"43","author":"A Cohen","year":"2018","unstructured":"Cohen A, Mandrekar J, St Louis EK, et al. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018;43:14\u20138.","journal-title":"Sleep Med"},{"key":"1141_CR83","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad161","author":"RH Ben-Joseph","year":"2023","unstructured":"Ben-Joseph RH, Saad R, Black J, et al. Cardiovascular burden of narcolepsy disease (CV-BOND): a real-world evidence study. Sleep. 2023;46(10):zsad161.","journal-title":"Sleep"},{"key":"1141_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101440","volume":"58","author":"PJ Jennum","year":"2021","unstructured":"Jennum PJ, Plazzi G, Silvani A, et al. Cardiovascular disorders in narcolepsy: review of associations and determinants. Sleep Med Rev. 2021;58: 101440.","journal-title":"Sleep Med Rev"},{"key":"1141_CR85","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1212\/WNL.0000000000004911","volume":"90","author":"A Bosco","year":"2018","unstructured":"Bosco A, Lopez R, Barateau L, et al. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. 2018;90:e479\u201391.","journal-title":"Neurology"},{"key":"1141_CR86","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/sleep\/30.10.1267","volume":"30","author":"D Chabas","year":"2007","unstructured":"Chabas D, Foulon C, Gonzalez J, et al. Eating disorder and metabolism in narcoleptic patients. Sleep. 2007;30:1267\u201373.","journal-title":"Sleep"},{"key":"1141_CR87","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41467-019-08774-1","volume":"10","author":"NW Pedersen","year":"2019","unstructured":"Pedersen NW, Holm A, Kristensen NP, et al. CD8(+) T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun. 2019;10:837.","journal-title":"Nat Commun"},{"key":"1141_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169836","volume":"12","author":"M Lecendreux","year":"2017","unstructured":"Lecendreux M, Churlaud G, Pitoiset F, et al. Narcolepsy type 1 is associated with a systemic increase and activation of regulatory T cells and with a systemic activation of global T cells. PLoS ONE. 2017;12: e0169836.","journal-title":"PLoS ONE"},{"key":"1141_CR89","doi-asserted-by":"publisher","first-page":"309","DOI":"10.14740\/jocmr4758","volume":"14","author":"FJ Martinez-Orozco","year":"2022","unstructured":"Martinez-Orozco FJ, Fernandez-Arquero M, Vicario JL, et al. Long-term outcome of a series of patients with narcolepsy type 1 and comorbidity with immunopathological and autoimmune diseases. J Clin Med Res. 2022;14:309\u201314.","journal-title":"J Clin Med Res"},{"key":"1141_CR90","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/aje\/kwn408","volume":"169","author":"EC Somers","year":"2009","unstructured":"Somers EC, Thomas SL, Smeeth L, Hall AJ. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169:749\u201355.","journal-title":"Am J Epidemiol"},{"key":"1141_CR91","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00125-011-2152-2","volume":"54","author":"M Skrzypski","year":"2011","unstructured":"Skrzypski M, Le TT, Kaczmarek P, et al. Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. Diabetologia. 2011;54:1841\u201352.","journal-title":"Diabetologia"},{"key":"1141_CR92","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.004","volume":"33","author":"J Black","year":"2017","unstructured":"Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13\u20138.","journal-title":"Sleep Med"},{"key":"1141_CR93","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4419-0854-4_10","volume-title":"Narcolepsy: a clinical guide","author":"LA Panossian","year":"2010","unstructured":"Panossian LA, Avidan AY. Narcolepsy and other comorbid medical illnesses. In: Goswami M, Pandi-Perumal SR, Thorpy MJ, editors. Narcolepsy: a clinical guide. Humana Press: New York; 2010. p. 105\u201314."},{"key":"1141_CR94","first-page":"16","volume":"6","author":"AM Morse","year":"2018","unstructured":"Morse AM, Sanjeev K. Narcolepsy and psychiatric disorders: comorbidities or shared pathophysiology? Med Sci (Basel). 2018;6:16.","journal-title":"Med Sci (Basel)."},{"key":"1141_CR95","doi-asserted-by":"publisher","first-page":"805","DOI":"10.5664\/jcsm.2926","volume":"9","author":"B Frauscher","year":"2013","unstructured":"Frauscher B, Ehrmann L, Mitterling T, et al. Delayed diagnosis, range of severity, and multiple sleep comorbidities: a clinical and polysomnographic analysis of 100 patients of the innsbruck narcolepsy cohort. J Clin Sleep Med. 2013;9:805\u201312.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR96","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-319-23739-8_12","volume-title":"Narcolepsy: a clinical guide","author":"R Peraita-Adrados","year":"2016","unstructured":"Peraita-Adrados R, Mart\u00ednez-Orozco FJ. Sleep disorder comorbidities in narcolepsy. In: Narcolepsy: a clinical guide. Cham: Springer; 2016. p. 161\u201375."},{"key":"1141_CR97","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.sleep.2011.01.010","volume":"12","author":"Y Dauvilliers","year":"2011","unstructured":"Dauvilliers Y, Bayard S, Shneerson JM, et al. High pain frequency in narcolepsy with cataplexy. Sleep Med. 2011;12:572\u20137.","journal-title":"Sleep Med"},{"key":"1141_CR98","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0304-3959(00)00470-X","volume":"92","author":"S Bingham","year":"2001","unstructured":"Bingham S, Davey PT, Babbs AJ, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain. 2001;92:81\u201390.","journal-title":"Pain"},{"key":"1141_CR99","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.bjp.0704851","volume":"137","author":"T Yamamoto","year":"2002","unstructured":"Yamamoto T, Nozaki-Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol. 2002;137:170\u20136.","journal-title":"Br J Pharmacol"},{"key":"1141_CR100","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5665\/sleep.2706","volume":"36","author":"P Jennum","year":"2013","unstructured":"Jennum P, Ibsen R, Knudsen S, Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep. 2013;36:835\u201340.","journal-title":"Sleep"},{"key":"1141_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101669","volume":"65","author":"S Gudka","year":"2022","unstructured":"Gudka S, Haynes E, Scotney J, et al. Narcolepsy: comorbidities, complexities and future directions. Sleep Med Rev. 2022;65: 101669.","journal-title":"Sleep Med Rev"},{"key":"1141_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189231","volume":"12","author":"CP Yang","year":"2017","unstructured":"Yang CP, Hsieh ML, Chiang JH, et al. Migraine and risk of narcolepsy in children: a nationwide longitudinal study. PLoS ONE. 2017;12: e0189231.","journal-title":"PLoS ONE"},{"key":"1141_CR103","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.sleep.2020.09.017","volume":"75","author":"AY Avidan","year":"2020","unstructured":"Avidan AY, Kushida CA. The sodium in sodium oxybate: is there cause for concern? Sleep Med. 2020;75:497\u2013501.","journal-title":"Sleep Med"},{"key":"1141_CR104","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5664\/jcsm.27549","volume":"5","author":"YG Wang","year":"2009","unstructured":"Wang YG, Swick TJ, Carter LP, et al. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5:365\u201371.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR105","doi-asserted-by":"publisher","first-page":"795","DOI":"10.5665\/sleep.3592","volume":"37","author":"CEHM Donjacour","year":"2014","unstructured":"Donjacour CEHM, Aziz NA, Overeem S, et al. Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep. 2014;37:795\u2013801.","journal-title":"Sleep"},{"key":"1141_CR106","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.sleep.2008.05.012","volume":"10","author":"AM Husain","year":"2009","unstructured":"Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009;10:661\u20133.","journal-title":"Sleep Med"},{"key":"1141_CR107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.sleep.2022.08.005","volume":"100","author":"A Malhotra","year":"2022","unstructured":"Malhotra A, Strollo PJ Jr, Pepin JL, et al. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Med. 2022;100:165\u201373.","journal-title":"Sleep Med"},{"key":"1141_CR108","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12684","volume":"28","author":"MS Schinkelshoek","year":"2019","unstructured":"Schinkelshoek MS, Smolders IM, Donjacour CE, et al. Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. J Sleep Res. 2019;28: e12684.","journal-title":"J Sleep Res"},{"key":"1141_CR109","volume-title":"Xyrem\u2122 (sodium oxybate oral solution, CIII). Full Prescribing Information","author":"Jazz Pharmaceuticals Inc","year":"2023","unstructured":"Jazz Pharmaceuticals Inc. Xyrem\u2122 (sodium oxybate oral solution, CIII). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals; 2023."},{"key":"1141_CR110","unstructured":"Janssen Pharmaceuticals, Inc. Concerta (methylphenidate hydrochloride tablet, extended release). Full Prescribing Information. Titusville, NJ; 2024."},{"key":"1141_CR111","unstructured":"Takeda Pharmaceuticals America, Inc. Adderall XR (dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release). Full Prescribing Information. Lexington, MA; 2023."},{"key":"1141_CR112","unstructured":"Takeda Pharmaceuticals USA, Inc. VYVANSE (lisdexamfetamine dimesylate capsules, for oral use, CII). Full Prescribing Information. Lexington, MA; 2021."},{"key":"1141_CR113","unstructured":"Teva Pharmaceuticals USA, Inc. Adderall (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate). Full Prescribing Information. Horsham, PA; 2017."},{"key":"1141_CR114","volume-title":"Sunosi (solriamfetol) Full Prescribing Information","author":"Axsome Therapeutics","year":"2023","unstructured":"Axsome Therapeutics. Sunosi (solriamfetol) Full Prescribing Information. New York: Axsome Therapeutics; 2023."},{"key":"1141_CR115","unstructured":"Harmony Biosciences, LLC. Wakix (pitolisant). Full Prescribing Information. Plymouth Meeting, PA; 2024."},{"key":"1141_CR116","volume-title":"Provigil (modafinil). Full Prescribing Information","author":"Teva Pharmaceuticals","year":"2022","unstructured":"Teva Pharmaceuticals. Provigil (modafinil). Full Prescribing Information. Parsippany: Teva Pharmaceuticals; 2022."},{"key":"1141_CR117","volume-title":"Nuvigil (armodafinil). Full Prescribing Information","author":"Teva Pharmaceuticals","year":"2022","unstructured":"Teva Pharmaceuticals. Nuvigil (armodafinil). Full Prescribing Information. Parsippany: Teva Pharmaceuticals; 2022."},{"key":"1141_CR118","first-page":"974","volume":"9","author":"IH Chung","year":"2022","unstructured":"Chung IH, Chin WC, Huang YS, Wang CH. Pediatric narcolepsy-a practical review. Children (Basel). 2022;9:974.","journal-title":"Children (Basel)."},{"key":"1141_CR119","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0009922820903434","volume":"59","author":"JA Owens","year":"2020","unstructured":"Owens JA, Babcock D, Weiss M. Evaluation and treatment of children and adolescents with excessive daytime sleepiness. Clin Pediatr (Phila). 2020;59:340\u201351.","journal-title":"Clin Pediatr (Phila)"},{"key":"1141_CR120","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004583-199407000-00009","volume":"33","author":"RE Dahl","year":"1994","unstructured":"Dahl RE, Holttum J, Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry. 1994;33:834\u201341.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1141_CR121","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/sleep\/17.suppl_8.S17","volume":"17","author":"MJ Challamel","year":"1994","unstructured":"Challamel MJ, Mazzola ME, Nevsimalova S, et al. Narcolepsy in children. Sleep. 1994;17:S17-20.","journal-title":"Sleep"},{"key":"1141_CR122","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1093\/brain\/awt277","volume":"136","author":"F Pizza","year":"2013","unstructured":"Pizza F, Franceschini C, Peltola H, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136:3787\u201395.","journal-title":"Brain"},{"key":"1141_CR123","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.21965","volume":"23","author":"L Serra","year":"2008","unstructured":"Serra L, Montagna P, Mignot E, et al. Cataplexy features in childhood narcolepsy. Mov Disord. 2008;23:858\u201365.","journal-title":"Mov Disord"},{"key":"1141_CR124","first-page":"106","volume":"7","author":"AM Morse","year":"2019","unstructured":"Morse AM. Narcolepsy in children and adults: a guide to improved recognition, diagnosis and management. Med Sci (Basel). 2019;7:106.","journal-title":"Med Sci (Basel)."},{"key":"1141_CR125","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11940-017-0459-0","volume":"19","author":"S Pillen","year":"2017","unstructured":"Pillen S, Pizza F, Dhondt K, et al. Cataplexy and its mimics: clinical recognition and management. Curr Treat Options Neurol. 2017;19:23.","journal-title":"Curr Treat Options Neurol"},{"key":"1141_CR126","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5665\/sleep.2366","volume":"36","author":"F Poli","year":"2013","unstructured":"Poli F, Pizza F, Mignot E, et al. High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy. Sleep. 2013;36:175\u201381.","journal-title":"Sleep"},{"key":"1141_CR127","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5664\/jcsm.8774","volume":"17","author":"DG Ingram","year":"2021","unstructured":"Ingram DG, Jesteadt L, Crisp C, Simon SL. Perceived challenges in pediatric narcolepsy: a survey of parents, youth, and sleep physicians. J Clin Sleep Med. 2021;17:13\u201322.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR128","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/cns.13811","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Thieux M, Inocente CO, et al. Characterization of rapid weight gain phenotype in children with narcolepsy. CNS Neurosci Ther. 2022;28:829\u201341.","journal-title":"CNS Neurosci Ther"},{"key":"1141_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101683","volume":"65","author":"S Melzi","year":"2022","unstructured":"Melzi S, Prevot V, Peyron C. Precocious puberty in narcolepsy type 1: orexin loss and\/or neuroinflammation, which is to blame? Sleep Med Rev. 2022;65: 101683.","journal-title":"Sleep Med Rev"},{"key":"1141_CR130","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.5665\/sleep.4910","volume":"38","author":"M Lecendreux","year":"2015","unstructured":"Lecendreux M, Lavault S, Lopez R, et al. Attention-deficit\/hyperactivity disorder (ADHD) symptoms in pediatric narcolepsy: a cross-sectional study. Sleep. 2015;38:1285\u201395.","journal-title":"Sleep"},{"key":"1141_CR131","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11910-014-0469-1","volume":"14","author":"S Nevsimalova","year":"2014","unstructured":"Nevsimalova S. The diagnosis and treatment of pediatric narcolepsy. Curr Neurol Neurosci Rep. 2014;14:469.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1141_CR132","volume-title":"Wakix (pitolisant). Summary of Product Characteristics","author":"Bioprojet Pharma","year":"2023","unstructured":"Bioprojet Pharma. Wakix (pitolisant). Summary of Product Characteristics. Paris: Bioprojet Pharma; 2023."},{"key":"1141_CR133","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1741-7015-11-78","volume":"11","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Lopez R, Ohayon M, Bayard S. Hypersomnia and depressive symptoms: methodological and clinical aspects. BMC Med. 2013;11:78.","journal-title":"BMC Med"},{"issue":"459\u201374","key":"1141_CR134","first-page":"xi","volume":"17","author":"B Vitiello","year":"2008","unstructured":"Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17:459\u201374, xi","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"1141_CR135","volume-title":"PROVIGIL (modafinil). Full Prescribing Information","author":"Teva Pharmaceuticals","year":"2015","unstructured":"Teva Pharmaceuticals. PROVIGIL (modafinil). Full Prescribing Information. North Wales: Teva Pharmaceuticals; 2015."},{"key":"1141_CR136","volume-title":"NUVIGIL (armodafinil). Full Prescribing Information","author":"Teva Pharmaceuticals USA, Inc","year":"2017","unstructured":"Teva Pharmaceuticals USA, Inc. NUVIGIL (armodafinil). Full Prescribing Information. North Wales: Teva Pharmaceuticals USA Inc; 2017."},{"key":"1141_CR137","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.5664\/jcsm.7966","volume":"15","author":"M Pascoe","year":"2019","unstructured":"Pascoe M, Carter LP, Honig E, et al. Pregnancy and contraception experiences in women with narcolepsy: a Narcolepsy Network Survey. J Clin Sleep Med. 2019;15:1421\u20136.","journal-title":"J Clin Sleep Med"},{"key":"1141_CR138","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.sleep.2012.11.021","volume":"14","author":"M Thorpy","year":"2013","unstructured":"Thorpy M, Zhao CG, Dauvilliers Y. Management of narcolepsy during pregnancy. Sleep Med. 2013;14:367\u201376.","journal-title":"Sleep Med"},{"key":"1141_CR139","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamainternmed.2020.4009","volume":"181","author":"S Kaplan","year":"2021","unstructured":"Kaplan S, Braverman DL, Frishman I, Bartov N. Pregnancy and fetal outcomes following exposure to modafinil and armodafinil during pregnancy. JAMA Intern Med. 2021;181:275\u20137.","journal-title":"JAMA Intern Med"},{"key":"1141_CR140","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bcpt.12034","volume":"112","author":"D Dideriksen","year":"2013","unstructured":"Dideriksen D, Potteg\u00e5rd A, Hallas J, et al. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112:73\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1141_CR141","unstructured":"Moretti P, Menculini G, Gonfia L. Sleep disorders in pregnancy. In: Sleep medicine and the evolution of contemporary sleep pharmacotherapy. London: IntechOpen;  2019."},{"key":"1141_CR142","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0004-2022","volume":"18","author":"PF Wong","year":"2022","unstructured":"Wong PF, D\u2019Cruz R, Hare A. Sleep disorders in pregnancy. Breathe (Sheff). 2022;18: 220004.","journal-title":"Breathe (Sheff)"},{"key":"1141_CR143","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/epirev\/mxs009","volume":"35","author":"ME Salive","year":"2013","unstructured":"Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75\u201383.","journal-title":"Epidemiol Rev"},{"issue":"563\u201377","key":"1141_CR144","first-page":"vii","volume":"25","author":"A Yazdanyar","year":"2009","unstructured":"Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25:563\u201377, vii.","journal-title":"Clin Geriatr Med"},{"key":"1141_CR145","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71:2052\u201381.","journal-title":"J Am Geriatr Soc"},{"key":"1141_CR146","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","volume":"35","author":"P Drakatos","year":"2017","unstructured":"Drakatos P, Lykouras D, D\u2019Ancona G, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80\u20134.","journal-title":"Sleep Med"},{"key":"1141_CR147","volume-title":"Xyrem\u2122 (sodium oxybate). Full Prescribing Information","author":"Jazz Pharmaceuticals","year":"2023","unstructured":"Jazz Pharmaceuticals. Xyrem\u2122 (sodium oxybate). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals Inc; 2023."},{"key":"1141_CR148","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2458-5-86","volume":"5","author":"LA Talbot","year":"2005","unstructured":"Talbot LA, Musiol RJ, Witham EK, Metter EJ. Falls in young, middle-aged and older community dwelling adults: perceived cause, environmental factors and injury. BMC Public Health. 2005;5:86.","journal-title":"BMC Public Health"},{"key":"1141_CR149","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-319-23739-8_7","volume-title":"Narcolepsy","author":"N Cornay-Manalo","year":"2016","unstructured":"Cornay-Manalo N, Attarian H. Narcolepsy in the older adult. In: Narcolepsy. Cham: Springer; 2016. p. 69\u201380."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01141-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:08:06Z","timestamp":1743498486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01141-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":149,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01141-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"26 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as part of a journal supplement wholly funded by Avadel Pharmaceuticals (Chesterfield, MO, USA). The development of this manuscript was funded by Avadel Pharmaceuticals. Open access publication and publication costs were funded by Avadel Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.M.M. has served as a consultant, speaker, and\/or on advisory boards for Avadel Pharmaceuticals, Eisai, Harmony Biosciences, Jazz Pharmaceuticals, Alkermes, and Takeda Pharmaceutical Co; has received grant funding from National Institutes of Health, UCB Pharmaceuticals, Jazz Pharmaceuticals, ResMed Foundation, Coverys Foundation, Harmony Biosciences, and Geisinger Health Plan; is the CEO of DAMM Good Sleep, LLC; and serves as an advisor for Neura Health and Floraworks. S.K. has no disclosures to report at this time. S.H. has served as a speaker for Jazz Pharmaceuticals. She is on the advisory board of Wake Up Narcolepsy and Project Sleep and is the founder of NY Sleep and Psychology. M.G. is cofounder and executive director of Wake Up Narcolepsy, nonprofit 501c3 organization. The organization has received grant funding for narcolepsy educational and awareness initiatives from Avadel Pharmaceuticals, Axsome Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, Takeda Pharmaceuticals, and Alkermes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"A.M.M., S.Y.K., S.H., and M.G. were involved in the conceptualization, analysis of existing literature and data, and drafting\/critically revising the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}